Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Abstract Background Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ’s appli...
Main Authors: | Xiaoying Hou, Hongzhi Du, Yufei Deng, Haiping Wang, Jinmi Liu, Jialu Qiao, Wei Liu, Xiji Shu, Binlian Sun, Yuchen Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-023-04042-5 |
Similar Items
-
β-elemene combined with temozolomide in treatment of brain glioma
by: Xiaomin Zhang, et al.
Published: (2021-12-01) -
Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01) -
Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01) -
Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
by: Shigeo Ohba, et al.
Published: (2021-05-01) -
Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas
by: Jiapeng Liu, et al.
Published: (2024-04-01)